Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05880849 · ClinicalTrials.gov registry record · Phase 1
Choline Effects - Pre-symptomatic AD
A Phase 1 study, sponsored by Paul E Schulz.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT05880849 is a Phase 1 study that has completed, run by Paul E Schulz. The registered enrollment target is 15 participants.
The verdict
NCT05880849, a Phase 1 study, has completed, sponsored by Paul E Schulz.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety, tolerability, and effects of choline in people with increased risk of Alzheimer's Disease (AD), also known as pre-symptomatic AD. Choline is a dietary supplement, but is being investigated to see if it has any effects on the progression to AD.
Interventions
- DRUG Choline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2025-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05880849
The ClinicalTrials.gov registry entry for NCT05880849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Paul E Schulz, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Choline is the first listed.
NCT05880849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05880849 about?
NCT05880849 is a clinical study titled "Choline Effects - Pre-symptomatic AD". The purpose of this study is to test the safety, tolerability, and effects of choline in people with increased risk of Alzheimer's Disease (AD), also known as pre-symptomatic AD. Choline is a dietary supplement, but is being investigated to see if it has any effects on the progression to AD.
What is the current status of trial NCT05880849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2023-06-26. Estimated completion is 2025-10-10.
What interventions are being tested in trial NCT05880849?
The interventions under investigation include: Choline (DRUG).
Who is sponsoring clinical trial NCT05880849?
This trial is sponsored by Paul E Schulz, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.